Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b daratumumab + lenalidomide + dexamethasone (DRd) in transplant-ineligible newly diagnosed multiple myeloma (Japan)
jRCT2080223339Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Primary safety and tolerability endpoints. Started Sep 2016; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080223339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223339.